TrialNCT07038343
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Status
- RECRUITING
- Phase
- PHASE1, PHASE2
- Last update posted
- 09/04/2026
- Start
- 06/04/2025
- Sponsor
- Avenzo Therapeutics, Inc.
- Specialties
- oncology
Conditions: Solid Tumor Cancer; Locally Advanced; Metastatic Solid Tumors; Lung Cancers; Epithelial Tumor; Biliary Tract Cancer (BTC); Urothelial Cancer; Nasopharyngeal Cancers
Brief summary
This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy and potentially in combination therapy to patients with locally advanced or metastatic epithelial solid tumors.
Protocol documents and results are not hosted here. Verify every detail on ClinicalTrials.gov.